Impact of the COVID-19 Outbreak on the Management of Patients with Cancer Eric RaymondCatherine ThieblemontSandrine Faivre Review Article Open access 22 May 2020 Pages: 249 - 259
MicroRNAs (miRNAs) and Long Non-Coding RNAs (lncRNAs) as New Tools for Cancer Therapy: First Steps from Bench to Bedside Margherita RattiAndrea LampisJens C. Hahne Review Article Open access 25 May 2020 Pages: 261 - 278
Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review Aye Myat ThiSandar Tin TinJ. Mark Elwood Systematic Review 22 May 2020 Pages: 279 - 299
Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry Simon ChowdhuryAnders BjartellLuis Costa Original Research Article Open access 04 June 2020 Pages: 301 - 315
Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy Takanobu YamadaTsutomu HayashiTakashi Oshima Original Research Article 21 April 2020 Pages: 317 - 325
Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors Vincenzo FormicaCristina MorelliHendrik-Tobias Arkenau Original Research Article 24 May 2020 Pages: 327 - 336
Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis Ya ChenShuyuan WangBaohui Han Original Research Article 03 June 2020 Pages: 337 - 345
Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy Kosuke TakemuraTakeshi YuasaJunji Yonese Original Research Article 30 May 2020 Pages: 347 - 356
Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations Haiyan XuWeihua LiYan Wang Original Research Article 16 May 2020 Pages: 357 - 364
Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas Shengnan DingXia MaoJianfeng Zhou Original Research Article 03 June 2020 Pages: 365 - 375
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer Jörg HänzeMoritz WegnerAxel Hegele Original Research Article Open access 03 June 2020 Pages: 377 - 390
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance Domenica LorussoJesús García-DonasFlorence Joly Therapy in Practice Open access 03 June 2020 Pages: 391 - 406
Molecular Targeting of a BRAF Mutation in Pancreatic Ductal Adenocarcinoma: Case Report and Literature Review An-Katrien SeghersPieter-Jan CuyleEric Van Cutsem Therapy in Practice 03 June 2020 Pages: 407 - 410
Comment on: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study” Yusuf Ziya Şener Letter to the Editor 27 May 2020 Pages: 411 - 411
Authors’ Reply to Yusuf Ziya Sener: “Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study” Jwa Hoon KimJeong Eun KimYong Sang Hong Letter to the Editor 27 May 2020 Pages: 413 - 414
